<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在周三发布的一份报告中，Canaccord Genuity Group 的股票研究分析师将其目标价格从 147.00 美元上调至 148.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。Canaccord Genuity Group 的目标价格暗示该股票当前价格有 21.27% 的潜在上涨空间。</p>
<p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
<ul>
<li>中型股奇迹：三只在 5 月超越销售预期的股票</li>
</ul>
<p>TMDX 已经成为其他多份研究报告的主题。华尔街 Zen 在 10 月 18 日的研究报告中将 TransMedics Group 的股票评级从 “持有” 上调至 “买入”。Piper Sandler 在 10 月 30 日的报告中将 TransMedics Group 的目标价格从 145.00 美元下调至 140.00 美元，并对该公司给予 “增持” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 TransMedics Group 的 “持有（c）” 评级。Needham &amp; Company LLC 在 12 月 8 日的报告中将 TransMedics Group 的目标价格从 148.00 美元上调至 166.00 美元，并给予该公司 “买入” 评级。最后，Stifel Nicolaus 在 9 月 4 日的研究报告中开始覆盖 TransMedics Group。他们对该公司设定了 “持有” 评级和 115.00 美元的目标价格。六位投资分析师对该股票给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 144.25 美元。</p>
<p><strong>查看我们关于 TransMedics Group 的最新报告</strong></p>
<h2>TransMedics Group 股票下跌 2.4%</h2>
<ul>
<li>2025 年表现突出的三只医疗科技股票</li>
</ul>
<p>在周三的午盘交易中，TMDX 的股票下跌了 3.00 美元，跌至 122.05 美元。该公司的交易量为 471,370 股，而其平均交易量为 1,196,944 股。TransMedics Group 的 1 年最低价为 55.00 美元，1 年最高价为 156.00 美元。该公司的市值为 41.7 亿美元，市盈率为 49.28，贝塔值为 2.06。该公司的债务与股本比率为 1.43，速动比率为 7.13，流动比率为 7.69。该公司的 50 日简单移动平均线为 127.10 美元，200 日简单移动平均线为 123.00 美元。</p>
<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在 10 月 29 日最后发布了季度财报。该公司报告每股收益（EPS）为 0.66 美元，超出分析师共识预期的 0.37 美元，超出幅度为 0.29 美元。TransMedics Group 的净利润率为 16.20%，股本回报率为 31.42%。该公司在本季度的收入为 1.4382 亿美元，而共识预期为 1.4533 亿美元。在去年同期，该公司每股收益为 0.12 美元。该公司的季度收入同比增长 32.2%。作为一个整体，卖方分析师预计 TransMedics Group 在本年度将发布 1 美元的每股收益。</p>
<h2>TransMedics Group 的内部买卖</h2>
<ul>
<li>3 只高增长股票，交易者热爱，投资者应关注</li>
</ul>
<p>在相关消息中，首席财务官 Gerardo Hernandez 在 12 月 4 日的交易中出售了 920 股公司的股票。股票以平均价格 139.62 美元出售，总价值为 128,450.40 美元。出售完成后，首席财务官在公司中持有 15,064 股，价值 2,103,235.68 美元。这代表其持股减少了 5.76%。该交易已在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站获取。此外，董事 Edward M. Basile 在 10 月 29 日的交易中出售了 4,142 股股票。该股票以平均价格 130.45 美元出售，总交易额为 540,323.90 美元。出售后，该董事在公司中持有 2,866 股，价值约 373,869.70 美元。这代表其持股减少了 59.10%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士已出售 13,062 股公司股票，价值为 1,797,634 美元。当前 7.00% 的股票由内部人士持有。</p>
<h2>TransMedics Group 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Opal Wealth Advisors LLC 在第二季度购买了 TransMedics Group 的新头寸，价值约 26,000 美元。Whittier Trust Co. of Nevada Inc.在第三季度将其在 TransMedics Group 的持股增加了 981.0%。Whittier Trust Co. of Nevada Inc.现在持有 227 股公司股票，价值 26,000 美元，此前在上个季度又购买了 206 股。Salomon &amp; Ludwin LLC 在第三季度收购了 TransMedics Group 的新头寸，价值约 28,000 美元。Harvest Fund Management Co. Ltd 在第三季度购买了 TransMedics Group 的股票，价值约 29,000 美元。最后，Smartleaf Asset Management LLC 在第一季度将其在 TransMedics Group 的持股增加了 44.3%。Smartleaf Asset Management LLC 现在持有 440 股公司股票，价值 30,000 美元，此前在此期间又购买了 135 股。对冲基金和其他机构投资者持有该公司 99.67% 的股票。</p>
<h2>关于 TransMedics Group</h2>
<p>（获取免费报告）</p>
<p>TransMedics Group, Inc 是一家商业阶段的医疗科技公司，致力于为美国及国际上的终末期器官衰竭患者转变器官移植治疗。该公司提供器官护理系统（OCS），这是一种便携式器官灌注、优化和监测系统，利用其专有和定制的技术在人体外复制接收器官的近生理条件。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而非 TransMedics Group</li>
<li>特别股息为何对收入投资者来说可能是令人愉快的惊喜</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>特斯拉被高估了吗？可能是一个便宜货的两个理由</li>
<li>CD 计算器：定期存款计算器</li>
<li>这两只股票如何赢得 2025 年的人工智能竞赛——以及 2026 年有什么期待</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 TransMedics Group 吗？</h2>
<p>在考虑 TransMedics Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而 TransMedics Group 并不在名单上。</p>
<p>虽然 TransMedics Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TMDX

<p>Canaccord Genuity Group 将 TransMedics Group (NASDAQ:TMDX) 的目标价格从 147.00 美元上调至 148.00 美元，并维持 “买入” 评级，暗示潜在上涨幅度为 21.27%。其他分析师的评级则各有不同，有的下调评级，有的上调评级。该股票的共识评级为 “适度买入”，平均目标价格为 144.25 美元。近期内部交易包括首席财务官和一名董事的股票出售。公司报告了强劲的季度收益，年同比收入增长 32.2%</p>

<p>TransMedics Group (NASDAQ:TMDX - Get Free Report) had its price objective increased by equities research analysts at Canaccord Genuity Group from $147.00 to $148.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the stock. Canaccord Genuity Group's price target would suggest a potential upside of 21.27% from the stock's current price.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在周三发布的一份报告中，Canaccord Genuity Group 的股票研究分析师将其目标价格从 147.00 美元上调至 148.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。Canaccord Genuity Group 的目标价格暗示该股票当前价格有 21.27% 的潜在上涨空间。</p>
</div><p>Get <strong>TransMedics Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
</div><ul>
<li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股奇迹：三只在 5 月超越销售预期的股票</li>
</ul>
</div><p>TMDX has been the subject of a number of other research reports. Wall Street Zen upgraded shares of TransMedics Group from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, October 18th. Piper Sandler decreased their price target on TransMedics Group from $145.00 to $140.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday, October 30th. Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Needham &amp; Company LLC increased their price objective on TransMedics Group from $148.00 to $166.00 and gave the company a &#34;buy&#34; rating in a report on Monday, December 8th. Finally, Stifel Nicolaus began coverage on TransMedics Group in a research note on Thursday, September 4th. They set a &#34;hold&#34; rating and a $115.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $144.25.</p>
<div class="lb-trans"><p>TMDX 已经成为其他多份研究报告的主题。华尔街 Zen 在 10 月 18 日的研究报告中将 TransMedics Group 的股票评级从 “持有” 上调至 “买入”。Piper Sandler 在 10 月 30 日的报告中将 TransMedics Group 的目标价格从 145.00 美元下调至 140.00 美元，并对该公司给予 “增持” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 TransMedics Group 的 “持有（c）” 评级。Needham &amp; Company LLC 在 12 月 8 日的报告中将 TransMedics Group 的目标价格从 148.00 美元上调至 166.00 美元，并给予该公司 “买入” 评级。最后，Stifel Nicolaus 在 9 月 4 日的研究报告中开始覆盖 TransMedics Group。他们对该公司设定了 “持有” 评级和 115.00 美元的目标价格。六位投资分析师对该股票给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 144.25 美元。</p>
</div><p><strong>View Our Latest Report on TransMedics Group</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TransMedics Group 的最新报告</strong></p>
</div><h2>TransMedics Group Stock Down 2.4%</h2>
<div class="lb-trans"><h2>TransMedics Group 股票下跌 2.4%</h2>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表现突出的三只医疗科技股票</li>
</ul>
</div><p>Shares of TMDX traded down $3.00 during midday trading on Wednesday, hitting $122.05. The company had a trading volume of 471,370 shares, compared to its average volume of 1,196,944. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $156.00. The firm has a market capitalization of $4.17 billion, a P/E ratio of 49.28 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The company's 50-day simple moving average is $127.10 and its 200-day simple moving average is $123.00.</p>
<div class="lb-trans"><p>在周三的午盘交易中，TMDX 的股票下跌了 3.00 美元，跌至 122.05 美元。该公司的交易量为 471,370 股，而其平均交易量为 1,196,944 股。TransMedics Group 的 1 年最低价为 55.00 美元，1 年最高价为 156.00 美元。该公司的市值为 41.7 亿美元，市盈率为 49.28，贝塔值为 2.06。该公司的债务与股本比率为 1.43，速动比率为 7.13，流动比率为 7.69。该公司的 50 日简单移动平均线为 127.10 美元，200 日简单移动平均线为 123.00 美元。</p>
</div><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same quarter in the previous year, the firm earned $0.12 earnings per share. The firm's quarterly revenue was up 32.2% on a year-over-year basis. As a group, sell-side analysts expect that TransMedics Group will post 1 EPS for the current year.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在 10 月 29 日最后发布了季度财报。该公司报告每股收益（EPS）为 0.66 美元，超出分析师共识预期的 0.37 美元，超出幅度为 0.29 美元。TransMedics Group 的净利润率为 16.20%，股本回报率为 31.42%。该公司在本季度的收入为 1.4382 亿美元，而共识预期为 1.4533 亿美元。在去年同期，该公司每股收益为 0.12 美元。该公司的季度收入同比增长 32.2%。作为一个整体，卖方分析师预计 TransMedics Group 在本年度将发布 1 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at TransMedics Group</h2>
<div class="lb-trans"><h2>TransMedics Group 的内部买卖</h2>
</div><ul>
<li>3 High-Growth Stocks Traders Love and Investors Should Watch</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只高增长股票，交易者热爱，投资者应关注</li>
</ul>
</div><p>In related news, CFO Gerardo Hernandez sold 920 shares of the company's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares in the company, valued at $2,103,235.68. This represents a 5.76% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, Director Edward M. Basile sold 4,142 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the sale, the director owned 2,866 shares of the company's stock, valued at approximately $373,869.70. This represents a 59.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 13,062 shares of company stock valued at $1,797,634. 7.00% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Gerardo Hernandez 在 12 月 4 日的交易中出售了 920 股公司的股票。股票以平均价格 139.62 美元出售，总价值为 128,450.40 美元。出售完成后，首席财务官在公司中持有 15,064 股，价值 2,103,235.68 美元。这代表其持股减少了 5.76%。该交易已在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站获取。此外，董事 Edward M. Basile 在 10 月 29 日的交易中出售了 4,142 股股票。该股票以平均价格 130.45 美元出售，总交易额为 540,323.90 美元。出售后，该董事在公司中持有 2,866 股，价值约 373,869.70 美元。这代表其持股减少了 59.10%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士已出售 13,062 股公司股票，价值为 1,797,634 美元。当前 7.00% 的股票由内部人士持有。</p>
</div><h2>Institutional Trading of TransMedics Group</h2>
<div class="lb-trans"><h2>TransMedics Group 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in TransMedics Group during the second quarter worth about $26,000. Whittier Trust Co. of Nevada Inc. boosted its holdings in TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company's stock valued at $26,000 after purchasing an additional 206 shares in the last quarter. Salomon &amp; Ludwin LLC acquired a new position in TransMedics Group during the 3rd quarter worth approximately $28,000. Harvest Fund Management Co. Ltd purchased a new position in shares of TransMedics Group during the 3rd quarter worth approximately $29,000. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after buying an additional 135 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Opal Wealth Advisors LLC 在第二季度购买了 TransMedics Group 的新头寸，价值约 26,000 美元。Whittier Trust Co. of Nevada Inc.在第三季度将其在 TransMedics Group 的持股增加了 981.0%。Whittier Trust Co. of Nevada Inc.现在持有 227 股公司股票，价值 26,000 美元，此前在上个季度又购买了 206 股。Salomon &amp; Ludwin LLC 在第三季度收购了 TransMedics Group 的新头寸，价值约 28,000 美元。Harvest Fund Management Co. Ltd 在第三季度购买了 TransMedics Group 的股票，价值约 29,000 美元。最后，Smartleaf Asset Management LLC 在第一季度将其在 TransMedics Group 的持股增加了 44.3%。Smartleaf Asset Management LLC 现在持有 440 股公司股票，价值 30,000 美元，此前在此期间又购买了 135 股。对冲基金和其他机构投资者持有该公司 99.67% 的股票。</p>
</div><h2>About TransMedics Group</h2>
<div class="lb-trans"><h2>关于 TransMedics Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.</p>
<div class="lb-trans"><p>TransMedics Group, Inc 是一家商业阶段的医疗科技公司，致力于为美国及国际上的终末期器官衰竭患者转变器官移植治疗。该公司提供器官护理系统（OCS），这是一种便携式器官灌注、优化和监测系统，利用其专有和定制的技术在人体外复制接收器官的近生理条件。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than TransMedics Group</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
<li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li>
<li>Is Tesla Overvalued? 2 Reasons It Might Be a Bargain</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>How These 2 Stocks Won 2025's AI Race—And What's In Store for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 TransMedics Group</li>
<li>特别股息为何对收入投资者来说可能是令人愉快的惊喜</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>特斯拉被高估了吗？可能是一个便宜货的两个理由</li>
<li>CD 计算器：定期存款计算器</li>
<li>这两只股票如何赢得 2025 年的人工智能竞赛——以及 2026 年有什么期待</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TMDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 TransMedics Group 吗？</h2>
</div><p>Before you consider TransMedics Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 TransMedics Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而 TransMedics Group 并不在名单上。</p>
</div><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TransMedics Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Canaccord Genuity Group 的分析师表示，TransMedics Group（NASDAQ:TMDX）的股价预计将会上涨